Bevacizumab-Based Therapies in Malignant Tumors-Real-World Data on Effectiveness, Safety, and Cost.
Elena ChitoranVlad RotaruSinziana-Octavia IonescuAisa GelalCristina-Mirela CapsaRoxana-Elena BohilteaMadalina-Nicoleta MitroiuDragoș ȘerbanGiuseppe GulloDaniela-Cristina StefanLaurentiu SimionPublished in: Cancers (2024)
Bevacizumab remains a high-cost therapy, but it can add to clinical benefits (like overall survival, progression-free survival, and response rate) when used in conjunction with standard chemotherapy. Similar results as those presented in various controlled trials are observable even on unselected cohorts of patients in the uncontrolled conditions of "real-world" oncological practice. Off-label usage is encountered in clinical practice, and this aspect should be monitored given the potential adverse effects of the therapy.
Keyphrases
- free survival
- end stage renal disease
- clinical practice
- ejection fraction
- randomized controlled trial
- healthcare
- chronic kidney disease
- systematic review
- primary care
- metastatic colorectal cancer
- peritoneal dialysis
- stem cells
- prostate cancer
- emergency department
- electronic health record
- rectal cancer
- locally advanced
- radiation therapy
- risk assessment
- radical prostatectomy
- mesenchymal stem cells
- cell therapy
- artificial intelligence
- human health
- patient reported
- smoking cessation